Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $34.17

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $34.1667.

A number of research analysts have issued reports on XFOR shares. HC Wainwright set a $3.50 target price on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. Stifel Nicolaus decreased their target price on X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, August 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of X4 Pharmaceuticals in a research note on Friday. Finally, Zacks Research raised X4 Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. Kingdon Capital Management L.L.C. lifted its holdings in shares of X4 Pharmaceuticals by 41.8% in the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after purchasing an additional 2,063,000 shares in the last quarter. Pale Fire Capital SE lifted its holdings in shares of X4 Pharmaceuticals by 45.2% in the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after purchasing an additional 633,398 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of X4 Pharmaceuticals by 9.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock valued at $114,000 after purchasing an additional 43,320 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares in the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Stock Up 23.0%

Shares of X4 Pharmaceuticals stock opened at $3.80 on Thursday. The company has a quick ratio of 3.05, a current ratio of 3.19 and a debt-to-equity ratio of 19.10. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $26.83. The business has a fifty day simple moving average of $3.36 and a 200 day simple moving average of $3.21. The stock has a market cap of $43.36 million, a PE ratio of -0.26 and a beta of 0.54.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Friday, August 8th. The company reported ($3.47) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $1.06. X4 Pharmaceuticals had a negative return on equity of 375.31% and a negative net margin of 311.15%.The business had revenue of $1.97 million during the quarter, compared to analysts’ expectations of $1.62 million. Research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.